Bharat Biotech submits Covaxin phase 3 trial data to DCGI: Report

Published On 2021-06-22 06:30 GMT   |   Update On 2021-06-22 09:51 GMT

New Delhi: The Hyderabad-based Covid vaccine manufacturing company Bharat Biotech submitted data from the Phase III clinical trials of Covaxin to the Drugs Controller General of India (DCGI) over the weekend, according to government sources. "We have received the data from the phase III trials," a senior government official confirmed.Bharat Biotech's Covaxin is one of the three vaccines which...

Login or Register to read the full article

New Delhi: The Hyderabad-based Covid vaccine manufacturing company Bharat Biotech submitted data from the Phase III clinical trials of Covaxin to the Drugs Controller General of India (DCGI) over the weekend, according to government sources.

"We have received the data from the phase III trials," a senior government official confirmed.

Bharat Biotech's Covaxin is one of the three vaccines which are currently being used in India. The phase III data of its vaccine have been questioned various times and that is what makes the data crucial which will ascertain the efficacy of the vaccine.
The company has developed the vaccine in association with the Indian Council of Medical Research (ICMR).
In a press briefing a few days ago by the Union Health Ministry, Dr V K Paul, who is a member (Health) Niti Aayog and also the head of the Covid task force of the country, said that the company would be submitting the data within seven to eight days.




Tags:    
Article Source : ANI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News